Below is Alston & Bird’s
Health Care Week in Review, which provides a synopsis of the latest news in healthcare regulations, notices, and guidance; federal legislation and congressional committee action; reports, studies, and analyses; and other health policy news.
Week in Review Highlight of the Week:
This week, HHS issued a final rule intended to govern the administrative dispute process in the 340B Drug Pricing Program. Read more about the rule and other news below.
I. Regulations, Notices & Guidance
On December 8, 2020, the Food & Drug Administration (FDA) issued guidance entitled,
Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products. This draft guidance describes best practices to help minimize medication errors and otherwise avoid adoption of proprietary names that contribute to violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its implementing regulations. The draft guidance also describes the framework FDA uses i
and senator harris, who announced her candidacy for the democratic ticket for president in 2020 this weekend, he is running to finish what obama started. she is promising. everything. but what does this mean for america, and how well her medicaid for all agenda impact ? the long lines of the canadian health care service and our future. joining me now is the ceo of foxhall cardiology, and one of the premier cardiologists in the world. great to have you on. explain to the layman why this fantasy of medicare for all will be harmful to the practice of health care and their health care. i ll keep it very simple. let s use the analogy of a supermarket. it buys wholesale milk for $3 a gallon and sells it to the consumer for $1. the doctor is the farmer prayed for consumers the customer.